enGene
Latest round
- Series B
Last raised
- Jan 2015
Total raised
- $25M
Investors
- 4
About enGene
Established in 1999 and based in Quebec, Canada, enGene Inc. operates as a clinical-stage genetic medicines company. The company was founded by its CTO, Anthony T. Cheung. In February 2024, enGene Inc. The transaction is expected to close on February 16, 2024, subject to customary closing conditions. The company trades on the Nasdaq under the ticker symbol ENGN. enGene develops gene therapies. The company's primary technology is a non-viral gene delivery platform called DDX, which enables the delivery of multiple genes directly to mucosal tissues and other organs. The firm’s lead product, EG-70, is a non-viral immunotherapy in development for the treatment of non-muscle-invasive bladder cancer.
Who invested in enGene
4 investors across 2 rounds
See all investors in enGene
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about enGene
Who invested in enGene?
enGene has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has enGene raised?
enGene has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did enGene last raise money?
enGene's most recent round on record is a Series B, in Jan 2015.
What does enGene do?
Established in 1999 and based in Quebec, Canada, enGene Inc.
Where is enGene headquartered?
enGene is headquartered in Saint-Laurent, Canada.
Which VCs invest in companies like enGene?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at enGene's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like enGene? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.